Search

Water removal which is a key treatment goal of automated peritoneal dialysis (APD) can be assessed cycle-by-cycle using remote patient monitoring (RPM). We analysed ultrafiltration patterns during night APD following a dry day (APDDD; no daytime fluid exchange) or wet day (APDWD; daytime exchange). Ultrafiltration for each APD exchange were recorded for 16 days using RPM in 14 patients. The distributed model of fluid and solute transport was applied to simulate APD and to explore the impact of changes in peritoneal tissue hydration on ultrafiltration. We found lower ultrafiltration (mL, median [first quartile, third quartile]) during first and second vs. consecutive exchanges in APDDD (−61 [−148, 27], 170 [78, 228] vs. 213 [126, 275] mL; p WD (81 [−8, 176], 81 [−4, 192] vs. 115 [4, 219] mL; NS). Simulations in a virtual patient showed that lower ultrafiltration (by 114 mL) was related to increased peritoneal tissue hydration caused by inflow of 187 mL of water during the first APDDD exchange. The observed phenomenon of lower ultrafiltration during initial exchanges of dialysis fluid in patients undergoing APDDD appears to be due to water inflow into the peritoneal tissue, re-establishing a state of increased hydration typical for peritoneal dialysis.

Peritoneal dialysis (PD) related infections are associated with technique failure and mortality. The aim of this multicentre study was to examine epidemiology, treatment and outcomes of PD-related infections in Poland as well as practice patterns for prevention of these complications in the context of current ISPD recommendations. A survey on PD practices in relation to infectious complications was conducted in 11 large Polish PD centres. Epidemiology of peritonitis and exit-site infections (ESI) was examined in all patients treated in these units over a 2 year period. The study included data on 559 PD patients with 62.4% on CAPD. Practice patterns for prevention of infectious complications are presented. The rate of peritonitis was 0.29 episodes per year at risk, with Gram positive microorganisms responsible for more than 50% of infections and 85.8% effectively treated. Diagnosis and treatment followed ISPD guidelines however most units did not provide an anti-fungal prophylaxis. Although neither of the centres reported routine topical mupirocin on catheter exit-site, the rate of ESI was low (0.1 episodes per year at risk), with Staphylococcus aureus as most common pathogen and full recovery in 78.3% of cases. The study shows rewarding outcomes in prevention and treatment of PD-associated infections, mainly due to a thorough compliance with the current ISPD guidelines, although some deviations from the recommendations in terms of practice patterns have been observed. More studies are needed in large numbers of patients to differentiate the importance of specific recommendations and further support the guidelines.

Purpose It is advocated to delay the start of peritoneal dialysis (PD) at least 10–14 days after insertion of peritoneal catheter. The aim of this study was to investigate factors associated with catheter-related complications (CRC) in patients starting PD early (1–13 days) (ES) and late (14 days or more) (LS) after catheter implantation. Material/Methods Single center, retrospective analysis of CRC occurring within 14 days of follow up after peritoneal dialysis initiation in ES and LS group of patients. Results A total of 97 patients were analyzed. Seventy percent of them were ES. There were significantly more CRC in ES vs. LS (31% vs. 3%, p=0.01). Significantly more mechanical CRC occurred in ES than in LS (21% vs. 0%, p=0.01). Occurrence of infectious CRC did not differ between the groups. In multivariate analysis the only predictor of CRC development was the time elapsed between catheter insertion and beginning of PD (Odds Ratio [OR] 0.80 95% Confidence Interval [95% CI] 0.70–0.91; p=0.001). Conclusions Each day of delay of PD initiation following peritoneal catheter insertion decreases the odds for development of mechanical CRC.

In the course of chronic kidney disease (CKD) comes to the disturbances in mineral and bone metabolism and extra-skeletal calcification. In subsequent stages of CKD, these processes intensify, leading to a deterioration in the quality of life and disability. They are also a major cause of morbidity and mortality from cardiovascular causes in CKD. In 2005, the Organization of Kidney Disease: Improving Global Outcomes (KIDGO), proposed replacing the term Renal Osteodystrophy in mineral and bone complications CKD (chronic kidney disease mineral and bone related disorders; CKD-MBD) as the disorder is not confined to the skeleton. CKD-MBD is manifested by the presence of changes in laboratory tests (corrected serum calcium, organic phosphate, parathyroid hormone, concentrations of vitamin D derivatives), changes in bone (bone metabolism, bone mineralization and trabecular bone volume), the occurrence of calcifications in the soft tissues and the arterial vessels.

Background: Bleeding diathesis and simultaneous thrombotic complications may be seen in dialyzed patients. Erythropoietin may shift the precarious balance of the hemostatic system towards thrombosis. Thrombin activatable fibrinolysis inhibitor (TAFI) is a key protein linking coagulation and fibrinolysis. Methods: The effects of 3-month erythropoietin treatment on some hemostatic parameters – TAFI, fibrinolytic activity index (FAI), markers of ongoing coagulation (thrombin-antithrombin complexes and prothrombin fragments 1 + 2), marker of ongoing fibrinolysis (plasmin-antiplasmin complexes) and marker of endothelial cell injury (thrombomodulin) – were studied in 17 patients on continuous ambulatory peritoneal dialysis (CAPD). Patients on CAPD not treated with rHuEPO were also studied. Healthy volunteers served as a control group. 2,000 U erythropoietin was given subcutaneously three times a week. Commercially available kits were used to determine hemostatic parameters. Results: All the hemostatic parameters studied were significantly higher in CAPD patients when compared to the control group. All these hemostatic parameters except the plasmin-antiplasmin complexes did not differ significantly between patients before rHuEPO therapy and patients without rHuEPO. Erythropoietin therapy resulted in a significant decrease in plasmin-antiplasmin complexes, a significant rise in FAI after 3 months of drug administration, and a tendency to decrease the TAFI concentration and activity (after 1 month, p = 0.11 and p = 0.10, respectively; after 3 months p = 0.07 and p = 0.06, respectively). Treatment with erythropoietin did not affect platelet count, prothrombin time, activated partial thromboplastin time, cholesterol, triglycerides, fibrinogen, total protein, albumin, serum iron, ferritin, fibronectin, pH, bicarbonates, creatinine, and urea. Hemoglobin and hematocrit increased significantly after 1 month of the therapy. Conclusion: Short-term treatment with erythropoietin seems to minimally affect hemostasis in CAPD patients.

In chronic renal failure, disturbances in hemostasis are predominantly due to the defective platelet function and platelet/vessel wall interactions. Erythropoietin, used in the treatment of renal anemia, affects hemostasis in dialyzed patients. The work was aimed at assessing the components of extrinsic coagulation pathway in patients on continuous ambulatory peritoneal dialysis (CAPD) in the course of erythropoietin therapy. The studies were performed on 11 CAPD patients, administered with subcutaneous erythropoietin in a dose of 2000 U three times a week for a 3 months time. Hemoglobin, hematocrit and erythrocyte count increased significantly after 1 month of the treatment. Tissue factor, tissue factor pathway inhibitor (total, free and truncated), factor VII and X as well as thrombomodulin-marker of endothelial celi injury did not change significantly during 3 months of erythropoietin therapy when compared to the baseline values. Erythropoietin treatment in CAPD patients did not affect significantly extrinsic coagulation pathway and endothelial function.

ObjectiveBleeding diathesis and simultaneous thrombotic complications may be seen in dialyzed patients. Erythropoietin (EPO) may shift the precarious balance of the hemostatic system toward thrombosis. Platelets and tissue factor (TF) play a major role in plug formation. Tissue factor pathway inhibitor (TFPI) appears to play a primary role in regulating TF-induced coagulation. Thrombin activatable fibrinolysis inhibitor (TAFI) is a key protein linking coagulation and fibrinolysis. The aim of the study was to assess whether 6 months of EPO therapy affects platelet function, that is, platelet aggregation and P-selectin level; moieties of the extrinsic coagulation pathway: TF, TFPI, and TFPI/Xa complexes, and factors VII and X; markers of ongoing coagulation: thrombin–antithrombin complexes (TAT) and prothrombin fragments 1+2; a marker of ongoing fibrinolysis: plasmin–antiplasmin complexes (PAP); fibrinolytic activity: euglobulin clot lysis time (ECLT); and markers of endothelial cell injury: von Willebrand factor, thrombomodulin, E-selectin, and TAFI, in continuous ambulatory peritoneal dialysis (CAPD) patients.Patients and Methods22 patients on CAPD were given EPO 6000 U/week. 12 patients with chronic renal failure and 12 healthy volunteers served as control groups. All parameters were studied before, and after 1, 3, and 6 months of EPO therapy.SettingDepartment of Nephrology and Internal Medicine, Medical Academy of Bialystok, Poland.ResultsPlatelet aggregation in whole blood did not change significantly during EPO treatment. A significant rise in arachidonic acid-induced platelet aggregation in platelet-rich plasma was observed after 3 and 6 months, and in collagen-induced platelet aggregation after 6 months of EPO therapy, compared to the baseline values. The TFPI concentration decreased significantly after 6 months of EPO therapy. The activity of factor VII increased transiently after 1 month of EPO therapy, compared to the baseline values. The TAFI concentration and activity in the CAPD group were significantly higher than in the control group. Erythropoietin therapy resulted in a significant decrease in TAFI concentration and activity after 6 months of EPO treatment. The ECLT was shortened significantly as early as after 1 month of EPO therapy. Thrombomodulin, von Willebrand factor concentration and activity, PAP, TAT, TFPI/Xa complexes, prothrombin fragments 1+2, factor X activity, P-selectin, E-selectin, and lipoprotein(a) did not change significantly during EPO treatment.ConclusionErythropoietin treatment has a minimal effect on hemostasis in CAPD patients. A tendency toward a decline in TAFI is of unknown clinical relevance so far, and awaits further research.